Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570542 · ClinicalTrials.gov registry record · Phase 2
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) and Refractory Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 14
- Study locations
NCT02570542: Active Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) and Refractory Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center.
NCT02570542 is a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) and Refractory Diffuse Large B Cell Lymphoma (DLBCL) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 59 participants, below the 257-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (77% lower). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570542, a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) and Refractory Diffuse Large B Cell Lymphoma (DLBCL), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.
Primary Outcome
equals date of progression/death - date of Autologous Stem Cell Transplantation
Conditions Studied
Interventions
- DRUG Plerixafor
- PROCEDURE leukapheresis
- DRUG carmustine, etoposide, cytarabine, melphalan
- PROCEDURE Autologous Stem Cell Transplantation
Study Locations (14)
New York
- Memorial Sloan Kettering Commack (Consent and Follow-up Only) - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Northwell Health (Data collection only) - Manhasset
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University - New York
- University of Rochester Medical Center - Rochester
- Memorial Sloan Kettering Nassau (Consent and Follow up Only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and Follow up Only) - Middletown
- Memorial Sloan Kettering Bergen (Consent and Follow Up Only) - Montvale
Nebraska
- University of Nebraska Medical Center - Omaha
Tennessee
- Tennessee Oncology - Nashville
Texas
- Texas Transplant Institute - San Antonio
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT02570542 still lists
NCT02570542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 257-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Diffuse Large B Cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 4 interventions - of which Plerixafor is the first listed.
NCT02570542 lists 14 locations in 6 states (New York, New Jersey, Nebraska).
Frequently Asked Questions
What is clinical trial NCT02570542 about?
NCT02570542 is a clinical study titled "Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)". The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.
What is the current status of trial NCT02570542?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2015-10. Estimated completion is 2026-10.
What conditions does trial NCT02570542 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT02570542?
The interventions under investigation include: Plerixafor (DRUG), leukapheresis (PROCEDURE), carmustine, etoposide, cytarabine, melphalan (DRUG), Autologous Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02570542?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02570542 being conducted?
This trial has 14 study locations across Nebraska, New Jersey, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma (DLBCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02570542's enrollment target sits among peer trials
59 7th of 10 higher than 4 of 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma (DLBCL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
RECRUITING · Phase 2
-
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
COMPLETED · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia